A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Completed · Phase 3

Conditions studied: HIV Infections

In brief

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

Key facts

Study ID

NCT00038636

Run by

Abbott

People needed

36

Starts

2000-09-01

Last updated by the study team

2006-08-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSD Treatment Center — San Diego, California, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Hopital Pitie-Salpetriere — Paris, France
• Hospital Europeen Georges Pompidou — Paris, France
• Hospital Clinico de Barcelona — Barcelona, Spain
• Ciutat Sanitaria de Bellvitge — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.